Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future
Author:
Affiliation:
1. Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE
2. Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, NC
Abstract
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.00512
Reference96 articles.
1. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
2. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
3. I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients
4. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
5. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma;Seminars in Oncology Nursing;2024-10
2. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19;Blood Cancer Journal;2024-07-10
3. Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study;HemaSphere;2024-07
4. Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma—Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries;International Journal of Molecular Sciences;2024-06-11
5. Novel treatment strategies for hematological malignancies in the immunotherapy era;International Journal of Hematology;2024-06-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3